X‑linked Insulin‑like Growth Factor 2 (IGF2) Deficiency

Overview

X‑linked IGF2 deficiency is a rare genetic disorder caused by loss‑of‑function mutations or deletions in the IGF2 gene located on the X chromosome (Xq26.2). IGF2 encodes insulin‑like growth factor‑2, a hormone that plays a critical role in fetal growth, brain development, and post‑natal metabolism. When IGF2 production is insufficient, affected individuals experience intra‑uterine growth restriction (IUGR), failure to thrive, and a spectrum of neuro‑developmental problems.

Because the gene is on the X chromosome, the condition follows an X‑linked recessive inheritance pattern. Males (who have a single X chromosome) are usually symptomatic, while females are typically carriers and may have milder or sub‑clinical features due to X‑inactivation.

Prevalence: Precise numbers are unknown because many cases remain undiagnosed, but recent population‑scale sequencing studies estimate a carrier frequency of roughly 1 in 5 000 to 1 in 10 000 females, translating to a clinical prevalence of < 0.01 % in males worldwide.¹

Symptoms

Symptoms may be evident at birth or develop during early childhood. The severity varies widely, even among brothers carrying the same mutation.

Growth‑related features

• Severe intra‑uterine growth restriction (IUGR) – birth weight often <10th percentile.
• Post‑natal failure to thrive – poor weight gain despite adequate nutrition.
• Short stature – height below the 3rd percentile after age 2.
• Microcephaly – head circumference <3rd percentile, reflecting reduced brain growth.

Neuro‑developmental manifestations

• Developmental delay – motor milestones such as sitting or walking may be delayed by months to years.
• Intellectual disability – ranging from mild (IQ 70‑85) to moderate (IQ 50‑70).
• Speech and language impairment – delayed first words, limited expressive language.
• Hypotonia – reduced muscle tone leading to floppy infant syndrome.
• Seizures – reported in ~15 % of affected males; may be focal or generalized.

Metabolic and endocrine signs

• Low serum IGF‑2 levels (often <50 % of age‑matched controls).
• Hypoglycemia – particularly in the neonatal period due to impaired hepatic glucose production.
• Altered lipid profile – low triglycerides and cholesterol in some patients.

Other possible findings

• Facial dysmorphism: narrow forehead, up‑slanting palpebral fissures, thin upper lip.
• Congenital heart defects (e.g., ventricular septal defect) in ~5 % of cases.
• Renal anomalies such as mild hydronephrosis.

Causes and Risk Factors

Genetic cause

The disorder results from loss‑of‑function mutations (nonsense, frameshift, splice‑site) or whole‑gene deletions of IGF2. Because the gene is imprinted (normally expressed only from the paternal allele), a mutation on the active paternal copy eliminates IGF2 production entirely, whereas a maternal mutation is usually silent due to imprinting.

Inheritance pattern

• X‑linked recessive – carrier mothers have a 50 % chance of passing the mutant allele to each son (who will be affected) and a 50 % chance of passing it to each daughter (who becomes a carrier).
• De novo mutations account for ~30 % of cases, meaning the mother does not carry the defect.

Risk factors

• Maternal carrier status (known family history of IGF2‑related growth disorders).
• Consanguinity increases the chance of recessive X‑linked disorders being reported in a family.
• Maternal exposure to agents that disrupt imprinting (e.g., assisted reproductive technologies) may theoretically influence expression, though data are limited.

Diagnosis

Because the phenotype overlaps with many other growth‑restriction syndromes, a systematic approach is essential.

Clinical evaluation

• Detailed prenatal and birth history (IUGR, birth weight/length percentiles).
• Growth charts plotted from birth onward.
• Neurological exam for hypotonia, reflexes, and developmental milestones.
• Family pedigree to assess X‑linked inheritance.

Laboratory tests

• Serum IGF‑2 level – measured by immunoassay; values <50 % of age‑matched norms raise suspicion.
• Comprehensive metabolic panel (glucose, liver enzymes, lipid profile) to detect hypoglycemia or hepatic involvement.
• Growth hormone (GH) stimulation test – usually normal, helping differentiate from GH deficiency.

Genetic testing

• Targeted IGF2 sequencing (Sanger or next‑generation sequencing) – confirms pathogenic variant.
• Copy‑number variant analysis (MLPA or chromosomal microarray) – detects whole‑gene deletions.
• Trio exome sequencing (child + parents) is increasingly used when the phenotype is unclear.

Imaging

• Brain MRI – may show reduced cortical volume or delayed myelination.
• Abdominal ultrasound – assesses liver size and rules out other causes of growth failure.
• Echocardiogram – indicated if cardiac murmurs or suspected congenital defects.

Diagnostic criteria (proposed)

Diagnosis is established when all three of the following are present:

1. Severe IUGR (<10th percentile) with post‑natal failure to thrive.
2. Serum IGF‑2 level ≤50 % of age‑matched reference.
3. Pathogenic variant or deletion of the paternal IGF2 allele confirmed by genetic testing.

Treatment Options

There is currently no cure, but multidisciplinary management can improve growth, neurodevelopment, and quality of life.

Growth‑promoting therapies

• Recombinant IGF‑2 (mecasermin‑LR) – experimental; early‑phase trials show modest increases in height velocity (≈4 cm/yr) and improved IGF‑2 serum levels. Not FDA‑approved for this indication (off‑label use may be considered under a clinical trial).
• Growth hormone (GH) therapy – generally not effective because the primary deficit is IGF‑2, but may be used if concurrent GH deficiency is documented.
• Nutrition optimization – high‑calorie, protein‑rich formulas; consider feeding specialist for tube feeding if oral intake insufficient.

Neurological and developmental support

• Early intervention programs (physical, occupational, speech therapy) initiated within the first 6 months of life.
• Anti‑seizure medications if seizures occur (e.g., levetiracetam, valproic acid). Choice guided by EEG pattern and side‑effect profile.
• Individualized education plans (IEPs) for school‑aged children.

Metabolic management

• Frequent feedings or continuous overnight enteral feeds to prevent hypoglycemia.
• Glucose monitoring in infants; consider prophylactic dextrose gel for severe neonatal hypoglycemia.

Medical surveillance

• Annual growth assessment and endocrine review.
• Bi‑annual neuro‑developmental evaluation.
• Cardiac echo every 2–3 years if a structural defect was identified.

Lifestyle and supportive measures

• Balanced diet rich in complex carbohydrates and healthy fats.
• Regular, age‑appropriate physical activity to maintain muscle tone and bone health.
• Psychosocial counseling for patients and families to address coping and stigma.

Living with X‑linked IGF2 Deficiency

Daily management tips

• Set a feeding schedule – aim for 8–10 feeds/day in infants; incorporate calorie‑dense snacks for toddlers.
• Track growth – use a home growth chart app; bring records to each clinic visit.
• Stimulate development – tactile, auditory, and visual toys; reading aloud daily.
• Monitor blood sugar – especially in the first 2 years; a glucometer at home is helpful.
• Maintain vaccination schedule – children with growth disorders may have altered immune responses; discuss with pediatrician.
• Family education – provide genetic counseling to parents and siblings.

Support networks

Organizations such as the National Organization for Rare Disorders (NORD) and disease‑specific parent groups can offer emotional support, research updates, and tips for navigating insurance.

Prevention

Because X‑linked IGF2 deficiency is a genetic condition, primary prevention is not possible. However, families can reduce the risk of having an affected child through:

• Carrier testing for at‑risk women (e.g., sisters of known carriers).
• Pre‑implantation genetic diagnosis (PGD) during in‑vitro fertilization to select embryos without the pathogenic IGF2 allele.
• Prenatal genetic testing (chorionic villus sampling or amniocentesis) if there is a known familial mutation.

Counseling should be offered by a certified genetic counselor experienced in X‑linked disorders.

Complications

If left untreated or inadequately managed, individuals may experience:

• Severe short stature – adult height often <150 cm in males.
• Profound intellectual disability – limiting independence.
• Recurrent hypoglycemic seizures – can cause permanent brain injury.
• Osteopenia/osteoporosis – due to poor nutrition and limited weight‑bearing activity.
• Cardiovascular strain – secondary to chronic under‑nutrition.
• Psychosocial disorders – anxiety, depression, and social isolation.

When to Seek Emergency Care

---

Sources: 1. Lek et al., *The Genome Aggregation Database* (gnomAD) 2023; 2. Mayo Clinic. “Growth disorders in children.” 2022; 3. National Institute of Child Health and Human Development. “IGF‑2 and fetal growth.” 2021; 4. WHO. “Rare diseases: technical report.” 2020; 5. Cleveland Clinic. “Management of intrauterine growth restriction.” 2023.